Navigation Links
Soligenix Submits NIAID Contract Proposal for Development of a Thermostable Ricin Vaccine
Date:10/31/2013

y significant preclinical survival results in a canine model of GI ARS funded by the NIAID.  Recently, Soligenix announced a worldwide exclusive collaboration with Intrexon Corporation that will focus on the joint development of a treatment for Melioidosis, a high priority biothreat and an area of unmet medical need.

For further information regarding Soligenix, Inc., please visit the Company's website at www.soligenix.com.

This press release contains forward-looking statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations and clinical trial enrollment.  Statements that are not historical facts, such as "anticipates," "estimates," "believes," "intends," "potential," or similar expressions, are forward-looking statements.  These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements.  Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats conducting preclinical and clinical trials of vaccines, obtaining regulatory approvals and manufacturing vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to perfo
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
2. Soligenix Reports First Quarter 2012 Financial Results and Highlights Recent Accomplishments
3. Soligenix Reports Second Quarter 2012 Financial Results and Highlights Recent Accomplishments
4. Soligenix Announces Issuance of US Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
5. FDA Grants Soligenix Fast Track Designation for SGX203 for the Treatment of Pediatric Crohns Disease
6. Soligenix Reports Third Quarter 2012 Financial Results and Highlights Recent Accomplishments
7. FDA Grants Soligenix Fast Track Designation for OrbeShield(TM) for the Reduction of Mortality Associated with Gastrointestinal Acute Radiation Syndrome (GI ARS)
8. Soligenix Announces Formation of Oral Mucositis Medical Advisory Board
9. Soligenix to Present at 15th Annual BIO CEO & Investor Conference
10. Soligenix Receives IND Clearance from FDA to Initiate Clinical Program to Evaluate SGX942 for the Treatment of Oral Mucositis
11. Soligenix to Present at World Vaccine Congress & Expo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... NEW YORK, Aug 20, 2014 Reportlinker.com ... available in its catalogue: Global Patient ... This report analyzes the worldwide markets ... following Product Segments: Floor Scales, Infant & Baby ... report provides separate comprehensive analytics for the US, ...
(Date:8/19/2014)... 2014   Lincor Inc. today announced ... to New Jersey -based healthcare ... Health will deploy Lincor,s PatientLINC technology across its ... and Hoboken University Medical Center. Lincor,s ... solutions to help hospitals reach new levels of ...
(Date:8/19/2014)... , Aug. 19, 2014 /PRNewswire-iReach/ -- ChemImage founder ... present a scientific poster describing an innovative diagnostic procedure ... 2014: Shedding New Light on Disease (SPEC) conference in ... Dr. Treado,s poster entitled, "Development of in vitro Diagnostics ... will be discussed during the conference poster session on ...
Breaking Medicine Technology:Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19Lincor Announces Agreement With CarePoint Health For State-Of-The-Art Patient Engagement Technology 2ChemImage Scientists Present Latest Developments for in vitro Detection of Colorectal Cancer Using Raman Molecular Imaging (RMI) at International Conference Focused on Biomedical Applications of Raman Spectroscopy 2
... Claron Technology makes the PROFIT 200 list for ... developer Claron Technology, headquartered in Toronto, has been included ... Fastest-Growing Companies by PROFIT Magazine. Ranking Canada,s Fastest-Growing Companies ... country,s most successful growth companies. Published in the Summer ...
... a medical technology company developing a platform of endoscopically ... obesity and type 2 diabetes, announced today the completion ... led by Broadline Capital, a global private equity investment ... issued and pending patents, will use the funding to ...
Cached Medicine Technology:Claron Technology Makes the PROFIT 200 List for the Third Consecutive Year 2EndoSphere Inc. Announces Pivotal Financing Led by Broadline Capital 2
(Date:8/20/2014)... Gray HealthDay Reporter WEDNESDAY, ... rare, colds, flu and other minor infections might trigger a ... children, a new study suggests. Just five out of ... States, said Dr. Heather Fullerton, lead author of the study ... of California, San Francisco Benioff Children,s Hospital. "It seems infections ...
(Date:8/20/2014)... Doheny HealthDay Reporter WEDNESDAY, ... mastectomy has long been an option, but a new study ... "The most common reasons women didn,t undergo reconstruction was ... more surgery or they were focused on their cancer treatment," ... at Memorial Sloan Kettering Cancer Center, in New York City. ...
(Date:8/20/2014)... common approach to treating kidney failure by removing waste ... for people who suddenly developed the condition, in an ... School of Medicine. , Their findings, published online in ... an aggressive method that is standardly used for people ... benefit to the patient. , "Our findings question the ...
(Date:8/20/2014)... cancer - using Botox. A study presented in the ... shows that cancer growth could be suppressed by eliminating ... cancer stem cells. The approach thus treated the cancer. ... and efficient. The researchers have thus far tested the ... humans. , The nervous system is crucial in regulating ...
(Date:8/20/2014)... August 20, 2014 A common approach ... the blood did not improve survival chances for people ... by experts at the University of Pittsburgh School ... today in the journal PLOS One , suggest ... for people with sudden kidney failure, may not provide ...
Breaking Medicine News(10 mins):Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 2Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 3Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:Treating gastric cancer -- with Botox 2Health News:Pitt Analysis Questions Use of Acute Hemodialysis Treatment 2
... to cover the American Stroke Associations International Stroke Conference ... Ernest N. Morial Convention Center in New Orleans, La. ... world of medical scientists and physicians engaged in research ... death in the United States. Nearly 4,000 attendees ...
... 20, 2008 New data revealing decreasing trends in cancer ... cancer deaths in particular, highlight the remarkable benefits of ... these tests is unrealized for many Americans according to ... Racial minorities, uninsured Americans and even Medicare patients who ...
... Feb. 19 The Ensign,Group, Inc. (Nasdaq: ... the Ensign(TM) group of,skilled nursing, rehabilitative care ... Waverly Park skilled nursing facility in,Tucson, Arizona ... Facility,Program established by the Centers for Medicare ...
... November 5, 2007, under increasing,government pressure, Bayer Pharmaceuticals Corporation ... Trasylol after a Canadian clinical study,found the drug could ... other drugs.,The Food and Drug Administration asked the company ... during heart bypass surgery,pending detailed review of preliminary results ...
... findings show that a specialized virus with the ability to ... brains of mice and eliminate them. Healthy brain tissue remained ... The Journal of Neuroscience . With more research, the technique ... cancer in humans. , Most importantly, this study finds that ...
... Accenx Technologies, Inc., a,leading company in electronic ... solutions, announced today the launch of their,new Physician,s ... their,clients, such as large health systems, hospitals, and ... outreach programs, and connect,physician practices to RyTRAK HIE ...
Cached Medicine News:Health News:US cancer deaths down but far too few Americans screened for colon cancer 2Health News:US cancer deaths down but far too few Americans screened for colon cancer 3Health News:The Ensign Group Successfully Graduates Troubled Nursing Home from CMS Special Focus Facility Program 2Health News:The Ensign Group Successfully Graduates Troubled Nursing Home from CMS Special Focus Facility Program 3Health News:Randone Trasylol Lawsuit Profiled on CBS' '60 Minutes' 2Health News:Randone Trasylol Lawsuit Profiled on CBS' '60 Minutes' 3Health News:Randone Trasylol Lawsuit Profiled on CBS' '60 Minutes' 4Health News:Tumor-killing virus selectively targets diseased brain cells 2Health News:New Accenx Physician's Relations Department! Now At Your Service 2
... enzyme-linked immunosorbent assay for the ... IgG-class antibodies to Gliadin in ... intended to be used as ... of gastrointestinal disorders, mainly Coeliac ...
... assurance reagent in assays detecting IgG and IgM ... IgM), IgG and IgM antibodies to rubella virus ... antibodies to cytomegalovirus (CMV IgG and IgM), and ... types 1 and 2 (HSV-1 IgG, HSV-1 IgM, ...
... The Titan Procedure is a ... infrared light source to tighten skin ... The Titan heats the dermis to ... epidermis through continuous cooling. In addition, ...
... XLTEK lets you choose how to configure your ... the study to be performed we recommend ... your budget and clinical needs. How do we ... listen. The result? Kortex. The system that lets ...
Medicine Products: